Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 10/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.43 |
| ▸ | TNF | P01375 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825644 | 0.94 | PDE4B (0.52) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6025567 | 0.81 | PDE4B (0.64) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16702165 | 0.81 | PDE4B (0.46) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1583109 | 0.80 | PDE4B (0.66) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL5191733 | 0.79 | PDE4B (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6421294 | 0.79 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL537167 | 0.78 | PDE4B (0.68) | UTS2RPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5423831 | 0.77 | PDE4B (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL825653 | 0.77 | PDE4B (0.53) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9939312 | 0.76 | PDE4B (0.52) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3142663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-3065778-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015175956-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015069711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-2395995-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093588-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION (US) | 2010-08-19 | — | — | WO | disclosed |